PRE-MEETING SYMPOSIUM: ORAL PRESENTATIONS
Moderators:
María Casanova-Acebes. Spanish National Cancer Research Center (CNIO), Spain.
Eduardo Lopez Granados. University Hospital La Paz, Spain.

• More Information
  • O-01. DIFFERENCES IN CAR-T CELL KINETICS MONITORED BY MULTIPARAMETRIC FLOW CYTOMETRY: PEDIATRIC VS ADULT PATIENTS.
    
    Cuesta Martín De La Cámara, Ricardo¹; Aguilar Criado, Daniela¹; Miguel Berenguel, Laura¹; Martínez Feito, Ana²; López Granados, Eduardo³; Mirones Aguilar, Isabel⁴; González Martínez, Berta⁵; Pérez-Martínez, Antonio⁵; Sánchez Vadillo, Irene⁶; Jiménez Yuste, Víctor⁶; Sánchez Zapardiel, Elena².
    
    ¹La Paz University Hospital, Department of Immunology; ²La Paz University Hospital, Department of Immunology; La Paz Institute of Biomedical Research (IdiPAZ); ³La Paz University Hospital, Department of Immunology; La Paz Institute of Biomedical Research (IdiPAZ); Centre for Biomedical Network Research on Rare Diseases (CIBERER U767)); ⁴La Paz University Hospital, Advanced Therapy Medicinal Products Production Unit, Haemato-Oncology Department; ⁵La Paz University Hospital, Department of Paediatric Haemato-Oncology; La Paz University Hospital, Translational Research Unit in Paediatric Haemato-Oncology, Hematopoietic Stem Cell  transplantation and Cell Therapy; ⁶La Paz University Hospital, Department of Haematology.
  • O-02. VPROGRESS TOWARDS A PATIENT-SPECIFIC MONOCLONAL ANTIBODY IN SEZARYSYNDROME
    
    Herrero Alonso, Marta1; Marín, Ana V.1; F. Megino, Rebeca1; Dominguez, Mercedes2; Moreno, Inmaculada2;Gaspar, María L.1; Viñuela Martín, Marcos3; Real Arévalo, Irene3; Subiza, José L4; Ramiro, Almudena5;Cortegano, Isabel2; Regueiro, José R.1.
    
    ¹Universidad Complutense de Madrid; ²Servicio de Inmunología Microbiana, Centro Nacional deMicrobiología, Instituto de Investigación Carlos III; ³Clinical Immunology-Experimental and SurgeryDepartment, Hospital Clínico Universitario San Carlos; ⁴Inmunotek; ⁵Spanish National Centre forCardiovascular Research | CNIC · Department of Vascular Biology and Inflammation.
  • O-03. Boosting CAR-T Therapy in Osteosarcoma: Overcoming Barriers and Exploring Combination Strategies.
    
    Garcia-Rodriguez, Patricia¹; Hidalgo, Laura¹; Rodriguez-Milla, Miguel Ángel¹; Cubillo, Isabel¹; Moreno, Rafael²; Perez-Martinez, Antonio³; Garcia-Castro, Javier¹.
    
    ¹Instituto de Salud Carlos III; ²IDIBELL; ³IdiPaz.
  • O-04. RNA-based cell fate reprogramming for cancer immunotherapy
    
    Lourenço Vaz, Beatriz¹; Arh, Nejc²; F. Rosa, Fábio³; Pereira, Carlos-Filipe⁴.
    
    ¹CNC-UC - Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-517, Portugal; ²Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, BMC A12, 221 84 Lund, Sweden/ Wallenberg Centre for Molecular Medicine, Lund University, BMC A12, 221 84 Lund, Sweden; ³Asgard Therapeutics AB, Medicon Village, 223 63 Lund, Sweden; ⁴Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-517, Portugal/ Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, BMC A12, 221 84 Lund, Sweden/  Wallenberg Centre for Molecular Medicine, Lund University, BMC A12, 221 84 Lund, Sweden/ Asgard Therapeutics AB, Medicon Village, 223 63 Lund, Sweden.
  • O-05. Dual-targeted CAR-T cells secreting T Cell Engagers elicit enhanced cytotoxic responses compared to tandem CAR-T cells
    
    Arroyo-Ródenas, Javier¹; Díez-Alonso, Laura¹; Falgas, Aida²; Martínez-Moreno, Alba²; Gil-Etayo, Javier¹; Aguilar-Sopeña, Óscar³; Velasco-Sidro, Miriam¹; Bravo Martín, Clara³; Ramírez-Fernández, Ángel¹; Blanco, Belén¹; Roda-Navarro, Pedro⁴; Bueno, Clara²; Menéndez, Pablo²; Álvarez-Vallina, Luis¹.
    
    ¹Hospital Universitario 12 de Octubre; ²Josep Carreras Leukaemia Research Institute; ³Universidad Complutense; ⁴Universidad Complutense de Madrid.
  • O-06. Infectious Bursal Disease Virus (IBDV) as a potential oncolytic virotherapy against different tumor models
    
    Tur Planells, Vicent¹; Bykov, Yonina²; Dawodu, Gloria²; García, Noemi³; Rius, Sergio¹; Arranz, Javier¹; Rodríguez, Dolores⁴; Rodríguez, Jose Francisco⁴; Ayuso, Angel³; García Sastre, Adolfo²; Nistal Villán, Estanislao¹; Cuadrado Castaño, Sara².
    
    ¹CEU San Pablo University; ²Icahn School of Medicine at Mount Sinai; ³Francisco de Vitoria University; ⁴Centro Nacional de Biotecnología.

POSTER PRESENTATIONS
Evaluators:
Pascual Martinez. University of Alicante (UA), Spain.
Jana Baranda. San Pablo University (CEU), Spain.
Rafael Sirera. Universidad Politecnica de Valencia (UPV), Spain
Carmela Cela. Young SEI Group (GJSEI), Spain.

• More information
  • P1-01. STAb-T therapy for multiple myeloma: T lymphocytes secreting T cell engagers (STAb-T cells) demonstrate superior antitumor activity than CAR-T cells.
    
    Blanco, Belén¹; Díez-Alonso, Laura¹; Falgás, Aïda²; Gómez-Rosel, Marina¹; Jiménez-Reinoso, Anaïs¹; Romencín, Paola A²; Aguilar-Sopeña, Óscar³; Ramírez-Fernández, Ángel¹; Jara, María⁴; Solé, Francesc²; Valeri, Antonio⁵; García-Ortiz, Almudena⁵; Juan, Manel⁶; Martínez-López, Joaquín⁵; Roda-Navarro, Pedro³; Martín-Antonio, Beatriz⁷; Orfao, Alberto⁴; Méndez, Pablo⁸; Bueno, Clara⁹; Álvarez Vallina, Luis¹.
    
    ¹Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, MadridImmuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid; ²Josep Carreras Leukaemia Research Institute; ³Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense Lymphocyte Immunobiology Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12); ⁴Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), Universidad de Salamanca Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid  Biomedical Research Institute of Salamanca (IBSAL), Salamanca.; ⁵Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO) Hematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre,  Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12); ⁶Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona. Servei d’Immunologia, Hospital Clínic de Barcelona  Plataforma Immunoterapia, Hospital Sant Joan de Deu  Universitat de Barcelona; ⁷Department of Experimental Hematology, Instituto de Investigación Sanitaria Fundación Jiménez Diaz, (IIS-FJD), UAM; ⁸Josep Carreras Leukaemia Research Institute; Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III,  Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Instituto de Salud Carlos III  Department of Biomedicine, School of Medicine, Universitat de Barcelona  Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona,; ⁹Josep Carreras Leukaemia Research Institute, Barcelona Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III, Madrid Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid.
  • P1-02. Genome manipulation of parasitic nematodes: from vaccine development to drug discovery.
    
    Quinzo Albiño, Mónica Johana.
    
    CNM-ISCIII.
  • P1-03. CD4⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts
    
    Jiménez-Reinoso, Anaïs¹; Molero-Abraham, Magdalena²; Cirauqui, Cristina³; Blanco, Belén¹; Garrido-Martin, Eva M.⁴; Nehme-Álvarez, Daniel⁵; Domínguez-Alonso, Carmen¹; Ramírez-Fernández, Ángel¹; Díez-Alonso, Laura¹; Nuñez-Buiza, Ángel³; González-Murillo, África⁶; Tobes, Raquel⁷; Pareja, Eduardo⁷; Ramírez-Orellana, Manuel⁶; Rodríguez-Peralto, José L.⁸; Ferrer, Irene⁹; Zugazagoitia, Jon¹⁰; Paz-Ares, Luis¹¹; Álvarez-Vallina, Luis¹.
    
    ¹Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre. Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12). H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Centro Nacional de Investigaciones Oncológicas (CNIO).; ²Tumor Microenvironment and Immunotherapy Research Group, imas12. H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Sanitaria 12 de Octubre (imas12), CNIO.; ³H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Sanitaria 12 de Octubre (imas12), CNIO.; ⁴H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Sanitaria 12 de Octubre (imas12), CNIO. Spanish Center for Biomedical Research Network in Oncology (CIBERONC). Cell Biology. Research and Development. Oncology Business Unit. PharmaMar.; ⁵Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre. Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12).; ⁶Advanced Therapies Unit, Oncology, Hospital Infantil Universitario Niño Jesús. Fundación de Investigación Biomédica, Hospital Infantil Universitario Niño Jesús. Instituto de Investigación Sanitaria La Princesa.; ⁷Alamo blanco Research Association; ⁸Spanish Center for Biomedical Research Network in Oncology (CIBERONC). Department of Pathology, Hospital Universitario 12 de Octubre. Department of Pathology, Complutense University. Cutaneous Oncology Group, imas12.; ⁹H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Sanitaria 12 de Octubre (imas12), CNIO. Spanish Center for Biomedical Research Network in Oncology (CIBERONC); ¹⁰Tumor Microenvironment and Immunotherapy Research Group, imas12. H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Sanitaria 12 de Octubre (imas12), CNIO. Spanish Center for Biomedical Research Network in Oncology (CIBERONC). Department of Medical Oncology, Hospital Universitario 12 de Octubre; ¹¹H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Sanitaria 12 de Octubre (imas12), CNIO. Spanish Center for Biomedical Research Network in Oncology (CIBERONC). Department of Medical Oncology, Hospital Universitario 12 de Octubre. Department of Medicine, Complutense University.
  • P1-04. DEEP NECROTIC SKIN ULCERS AS AN ADVERSE EFFECT OF SUBCUTANEOUS IMMUNOGLOBULINS FACILITATED BY HYALURONIC ACID 
    
    Fernández Cabrera, Helena; Ferranti, Andrea Carolina; Vasquez Reyes, Paulina; Iguasnia Portilla, Brayan Daniel; García Trujillo, Jose Antonio; Fernández Pereira, Luis Miguel.
    
    Hospital San Pedro de Alcántara.
  • P1-05. A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
    
    Rubio Pérez, Laura¹; Lázaro-Gorines, Rodrigo²; Harwood, Seandean L.³; Compte, Marta⁴; Navarro, Rocío⁴; Tapia-Galisteo, Antonio⁵; Bonet, Jaume⁶; Blanco, Belén⁵; Lykkemark, Simon⁷; Ramírez-Fernández, Ángel⁸; Ferreras-Gutiérrez, Mariola⁹; Domínguez-Alonso, Carmen⁸; Díez-Alonso, Laura⁸; Segura-Tudela, Alejandro⁸; Hangiu, Oana¹⁰; Erce-Llamazares, Ainhoa¹⁰; Blanco, Francisco J.⁹; Santos, Cruz¹¹; Rodríguez-Peralto, José L¹²; Sanz, Laura¹³; Álvarez Vallina, Luis¹⁴.
    
    ¹Unidad de Inmunoterapia del Cáncer, Hospital 12 de Octubre; ²Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre;  Immuno-Oncology and  Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12); H12O-CNIO Cancer Immunotherapy Clinical  Research Unit, Spanish National Cancer Research Centre (CNIO); ³Department of Molecular Biology and Genetics, Aarhus University; ⁴Department of Antibody Engineering,  Leadartis SL, QUBE Technology Park; ⁵Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre; Immuno-Oncology and  Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12;  H12O-CNIO Cancer Immunotherapy Clinical  Research Unit, Spanish National Cancer Research Centre (CNIO); ⁶g Institute of Bioengineering, École Polytechnique Fédérale de Lausanne; ⁷Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University; ⁸Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre; Immuno-Oncology and  Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12);  H12O-CNIO Cancer Immunotherapy Clinical  Research Unit, Spanish National Cancer Research Centre (CNIO); ⁹Centro de Investigaciones  Biológicas Margarita Salas (CIB), CSIC; ¹⁰Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre;  Immuno-Oncology and  Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12);  Department of Antibody Engineering,  Leadartis SL, QUBE Technology Park; ¹¹Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV); ¹²Department of Pathology, Hospital Universitario 12 de Octubre; Department of Pathology, Universidad Complutense, Madrid, Spain; Cutaneous Oncology Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12);  Centro de Investigación Biomédica en Red  en Oncología (CIBERONC); ¹³Centro de Investigación Biomédica en Red en Oncología (CIBERONC); Molecular Immunology Unit, Hospital Universitario Puerta de Hierro; ¹⁴Cancer Immunitherapy Unit (UNICA), Deparment of Immunology, Hospital 12 de octubre; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de octubre (imas12); H12O-CNIO Cancer Immunotherapy Clinical REsearch Unit, Spanish National Cancer Research Center (CNIO); Chair for Immunology UFV/Merck, Universidad Francisco de Vitoria (UFV).
  • P1-06. EFFECTIVE MANAGEMENT OF HEREDITARY ANGIOEDEMA WITH LANADELUMAB: A CASE SERIES
    
    Ferranti-Ramos, Andrea; Vásquez Reyes, Paulina; Fernández Cabrera, Helena; Porcel Carreño, Sergio; Romero Chala, Silvia; Fernández Pereira, Luis Miguel.
    
    Complejo Hospitalario Universitario de Cáceres.
  • P1-07. TAP-independence presentation during a cytomegalovirus infection.
    
    Rodríguez-Rojas, Cristina; C. Méndez, Andrea; Mena-Romero, Beatriz; Antón, Luis C.; Del Val, Margarita.
    
    CBMSO (CSIC).
  • P1-08. Bacterioruberin-Induced Apoptosis: A Potential Natural Antitumor Strategy Against Myeloid Leukemia
    
    Baeza-Morales, Andrés; Medina-García, Miguel; Pujalte-Satorre, Carolina; Giani, Micaela; Pascual-García, Sandra; Martínez-Peinado, Pascual; López-Jaén, Ana Belén; Martínez-Espinosa, Rosa María; Sempere-Ortells, José Miguel.
    
    University of Alicante.
  • P1-09. Unconventional activation of the IRE1-XBP1 branch of the UPR is a host factor involved in the immunopathology of SARS-CoV-2
    
    Fernández, Jose Javier¹; Fernández, Nieves²; Sánchez Crespo, Mariano³.
    
    ¹CIB; ²UVa; ³IBGM.
  • P1-10. Conditioned media from MSCs promote an anti-inflammatory and immunosuppressant effect of PBMCs from RA patients through the activation of CTLA-4 and PD-1 markers.
    
    Pujalte Satorre, Carolina¹; Pascual García, Sandra¹; Baeza Morales, Andrés¹; Medina García, Miguel¹; Martínez Peinado, Pascual¹; Navarro Sempere, Alicia¹; Navarro Blasco, Francisco Javier²; Romera López, Cynthia²; Esteve Girbés, Jordi¹; López Jaén, Ana Belén¹; Sempere Ortells, José Miguel¹.
    
    ¹University of Alicante; ²Hospital General Universitario de Elche.
  • P1-11. Can a lung transplant be avoided through treatment with intravenous immunoglobulins?
    
    Mendoza Bravo, Daniel Albert; De Andrés Martin, Ana; Stewart  Delcid, Vivian Lizeth; Ferrez Hernández, Celia; Garcia De La Torre, Iván; Manterola Navarro, Elena.
    
    Hospital Universitario Ramon y Cajal.
  • P1-12. Trained immunity is induced by Heat-killed Mycobacterium tuberculosis when administered in vivo and in vitro
    
    Bravo-Robles, Laura¹; Minute, Luna¹; Bergón-Gutiérrez, Marta¹; Mata-Martínez, Pablo²; Fernández-Pascual, Jaime¹; Terrón, Verónica¹; Bıçakcıoğlu, Gülce¹; Zapata-Fernández, Gabriela¹; Aguilo, Nacho³; López-Collazo, Eduardo¹; Del Fresno, Carlos¹.
    
    ¹IdiPAZ; ²IdiPAZ and INMUNOTEK S.L.; ³Departamento de Microbiología, Pediatría, Radiología y Salud Pública, Universidad de Zaragoza/IIS.
  • P1-13. ABATACEPT: A PROMISING TARGETED TREATMENT FOR CTLA-4 HAPLOINSUFFICIENCY
    
    Jurado Orozco, Alicia; Morales Garcia, Carmen; Muñoz García, Raquel; Lucena Soto, Jose Manuel.
    
    HU Virgen Rocío.
  • P1-14. IMMUNOMODULATORY CAPACITY OF BACTERIORUBERIN ON PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCs)
    
    Medina García, Miguel; Baeza Morales, Andrés; Pujalte Satorre, Carolina; Martínez Peinado, Pascual; Pascual García, Sandra; Giani Alonso, Micaela; Martínez Espinosa, Rosa María; Sempere Ortells, José Miguel.
    
    Universidad de Alicante.
  • P1-15. Abatacept: our experience in a patient with long-term evolution CTLA4 haploinsufficiency
    
    Calvet Lacruz, Anna; Franco Leyva, Teresa; Bravo Gómez, Andrea Carolina; Boera Carnicero, Gemma; Calahorro Aguilar, Verónica; Roca Cano, Indra; Martínez Martínez, Laura; De La Calle Martín, Óscar.
    
    Hospital de la Santa Creu i Sant Pau.
  • P1-16. Acquisition of the embryonic program by myeloid-derived macrophages underlies asymmetrical, convergent epigenetic profiles.
    
    De La Calle-Fabregat, Carlos; Dunsmore, Garett; Blériot, Camille; Ginhoux, Florent.
    
    Institut Gustave Roussy.
  • P1-18. Analysis of the Influenza A virus and Staphylococcus aureus coinfection over the inflammatory response of BMDM and bacterial persistence.
    
    Inchausti-Moya, Inés; Reche  Sainz, María Paloma; Nistal-Villan, Estanislao; Rius-Rocabert, Sergio.
    
    San Pablo CEU University
  • P1-19. The NLRP3 inflammasome is activated by hemin and is implicated in renal damage associated with hemolytic diseases
    
    Caballero Herrero, María Josefa¹; Beltrán-Camacho, Lucia²; Vallejo-Mudarra, Mercedes²; Sánchez-Arcas, Lucía²; García-Caballero, Cristina²; Jumilla, Esther¹; Pérez Olmos, Antonio¹; Arias Sanchez, Celia¹; Pelegrin, Pablo³; Cuevas González, Santiago¹; Antonio Moreno, Juan².
    
    ¹FFIS-IMIB; ²IMIBIC; ³IMIB-University of Murcia(Department of Biochemistry and Molecular Biology B and Immunology).
  • P2-01. Development and optimization of a combinatorial CAR-T cell therapy for AML to overcome on target - off tumor responses
    
    Horndler, Lydia¹; Merino, Javier¹; Prieto, Cristina¹; Köhler, Natalia²; Minguet, Susana³; Zeiser, Robert²; Van Santen, Hisse¹.
    
    ¹CSIC; ²Medical School of University of Freiburg; ³University of Freiburg.
  • P2-02. IMMUNOMODULATORY TREATMENT WITH INTRAVENOUS IMMUNOGLOBULINS IN WOMEN WITH ALLOIIMMUNE REPRODUCTIVE FAILURE: OUR EXPERIENCE IN 8 YEARS.
    
    Vásquez Reyes, Paulina Belén; Fernandez Cabrera, Helena; Ferranti Ramos, Andrea; Vergara Prieto, Esther; Sobieschi, Oana Irina; Fernandez Pereira, Luis.
    
    Hospital San Pedro de Alcántara.
  • P2-04. Tumor cell secretome plasticity in resistant human leukemic cells as a key factor in the use of anticancer therapies.
    
    Cadenas Garrido, Paula¹; García Serna, Azahara M²; Parrado, Antonio²; Martínez García, Javier³; Cánovas, Manuel¹; De Diego Puente, Teresa¹; Saceda, Miguel⁴; Pelegrín, Pablo²; Martín-Orozco, Elena¹.
    
    ¹Universidad de Murcia; ²IMIB; ³Universidad de Zaragoza; ⁴Universidad Miguel Hernández.
  • P2-05. Exploring the immunosuppressive properties of lipid-laden macrophages and its clonal hematopoietic origin in ovarian cancer
    
    Martinez Pacheco, Sarai¹; Gómez Parrizas, Mónica¹; De Juan, Alba¹; Munarriz Paños, Mariola¹; Garvin Jiménez, Eduardo¹; Barrantes, Sandra¹; Sanguino, María Angeles²; Zuriaga Herrero, María Ángeles²; Fuster, José Javier²; Quail, Daniela³; Dimitri, Diletta⁴; Casanova Acebes, María¹.
    
    ¹Centro Nacional de Investigaciones Oncológicas; ²Centro Nacional de Investigaciones Cardiovasculares; ³The Goodman Cancer Institute; ⁴Instituto Clinico Humanitas IRCCS.
  • P2-06. A new and flexible vaccine platform for personalized cancer immunotherapy
    
    Barajas, Ana¹; Amengual-Rigo, Pep²; Pons-Grífols, Anna¹; Ortiz, Raquel¹; Gracia Carmona, Oriol²; Urrea, Victor¹; De La Iglesia, Núria¹; Blanco-Heredia, Juan¹; Anjos-Souza, Carla¹; Varela, Ismael¹; Trinité, Benjamin¹; Tarrés-Freixas, Ferran¹; Rovirosa, Carla¹; Lepore, Rosalba²; Vázquez, Miguel²; De Mattos-Arruda, Leticia¹; Valencia, Alfonso²; Clotet, Bonaventura¹; Aguilar-Gurrieri, Carmen¹; Guallar, Victor²; Carrillo, Jorge¹; Blanco, Julià¹.
    
    ¹IrsiCaixa AIDS Research Institute; ²Barcelona Supercomputing Center (BSC).
  • P2-07. Short alanine-based spacers included in poly-neoantigen vaccines improve peptide processing and presentation to CD8+ T cells
    
    Aguilar-Gurrieri, Carmen; Barajas, Ana; Rovirosa, Carla; Ortiz, Raquel; Urrea, Victor; De La Iglesia, Núria; Clotet, Bonaventura; Blanco, Julià; Carrillo, Jorge.
    
    IrsiCaixa AIDS Research Institute.
  • P2-08. DENDRITIC CELL-MEDIATED CROSS-PRIMING BY A BISPECIFIC NEUTRALIZING ANTIBODY BOOSTS CYTOTOXIC T CELL RESPONSES AND PROTECTS MICE AGAINST SARS-COV-2
    
    Lazaro Gorines, Rodrigo¹; Pérez, Patricia²; Heras, Ignacio³; Adán, Irene³; Segura, Alejandro⁴; Rubio, Laura⁴; Albericio, Guillermo²; Astorgano, David²; Luzkowiak, Joanna⁴; Labiod, Nuria⁴; Delgado, Rafa⁴; Weber, David⁵; Godoy, Raquel⁵; Muñoz, Inés¹; Blanco, Francisco⁶; Sancho, David³; García Arriaza, Juan²; Álvarez-Vallina, Luis¹.
    
    ¹Centro Nacional de Investigaciones Oncológicas; ²Centro Nacional de Biotecnología CNB-CSIC; ³Centro Nacional de Investigaciones Cardiovasculares; ⁴Hospital Universitario 12 de Octubre; ⁵Universidad de Maryland; ⁶Centro de Investigaciones Biológicas CSIC.
  • P2-09. Unravelling DC subsets and states across human healthy and malignant tissues
    
    Kong, Wan Ting¹; Mulder, Kevin¹; Dutertre, Charles-Antoine²; Ginhoux, Florent¹.
    
    ¹Institute Gustave Roussy; ²INSERM.
  • P2-10. MONITORING THE CELLULAR IMMUNE RESPONSE FOLLOWING SARS-COV-2 VACCINATION: A COMPARATIVE ANALYSIS OF AVAILABLE METHODS
    
    Muñoz Martinez, Sara¹; Márquez Leiva, Inmaculada¹; Berges Buxeda, Marcos Joaquin¹; Baranda, Jana¹; González Pérez, Maria¹; Conde, Patricia¹; Lozano Ojalvo, Daniel²; Cámara, Cármen³; Ochando, Jordi¹.
    
    ¹Instituto de Salud Carlos III; ²Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, .; ³Departamento de Immunologia, Hospital Universitario La Paz.
  • P2-11. Implementation of digital PCR for monitoring patients treated with CAR-T cell therapy
    
    Morales García, Carmen; Muñoz García, Raquel; Jurado Orozco, Alicia; García Lozano, Jose Raul; Lucena Soto, Jose Manuel.
    
    Hospital Universitario Virgen del Rocío.
  • P2-12. Evaluation of common immunosuppressants ability to inhibit trained immunity in vitro
    
    Berges Buxeda, Marcos J.¹; Baranda, Jana²; González Pérez, María¹; Márquez Leiva, Inmaculada¹; Muñoz Martínez, Sara¹; Conde, Patricia¹; Lozano Ojalvo, Daniel³; Ochando, Jordi¹.
    
    ¹Instituto de Salud Carlos III; ²Universidad CEU San Pablo; ³Icahn School of Medicine at Mount Sinai.
  • P2-13. The effect of high-salt diet in the immunology and development of hepatocellular carcinoma
    
    Tzoumpa, Amalia; Lozano-Luiz, Beatriz; Huang, Yin; Picó, Joanna; Gómez, Melisa; Zapater, Pedro; González-Navajas, Jose Manuel.
    
    Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) & Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd).
  • P2-14. TCR CDR3β sequence as a tool to follow up Sezary Syndrome patients
    
    Estevez-Benito, Ignacio; Chacon-Arguedas, D; Herrero-Alonso, M; Regueiro, José R; Marin, Ana V.
    
    Complutense University of Madrid.
  • P2-15. Monitorization of the cellular immune response to SARS-CoV-2 within the European clinical research network VACCELERATE
    
    Márquez Leiva, Inmaculada¹; Bergues-Buxeda, Marcos Joaquín¹; Muñoz-Martínez, Sara¹; Baranda, Jana¹; González-Pérez, María¹; Conde, Patricia¹; Cámara, Carmen²; Lozano-Ojalvo, Daniel¹; Ochando, Jordi¹.
    
    ¹Instituto de Salud Carlos III; ²Hospital Universitario de La Paz.
  • P2-16. New biomarker for unexpained reproductive failure
    
    Gil Laborda, Raquel¹; Rodriguez De Frias, Edgar²; Subhi-Issa, Nabil²; De La Fuente, Eduardo²; Sanchez-Ramon, Silvia²; Fernandez-Arquero, Miguel².
    
    ¹Hospital Clínico San Carlos; ²HCSC.
  • P2-17. FLOW CYTOMETRY FOR TISAGENLECLEUCEL AND DUAL-TARGET ANTI-CD19/CD22 CAR-T THERAPY MONITORING IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE
    
    Miguel Berenguel, Laura¹; Cuesta Martín De La Cámara, Ricardo¹; Aguilar Concepción, Daniela¹; Martínez Feito, Ana²; López Granados, Eduardo³; Mirones Aguilar, Isabel⁴; González Martínez, Berta⁵; Pérez Martínez, Antonio⁵; Sánchez Zapardiel, Elena².
    
    ¹La Paz University Hospital, Department of Immunology; ²La Paz University Hospital, Department of Immunology; La Paz Institute of Biomedical Research (IdiPAZ); ³La Paz University Hospital, Department of Immunology; La Paz Institute of Biomedical Research (IdiPAZ); Centre for Biomedical Network Research on Rare Diseases (CIBERER U767); ⁴La Paz University Hospital, Advanced Therapy Medicinal Products Production Unit, Haemato-Oncology Department; ⁵La Paz University Hospital, Department of Paediatric Haemato-Oncology; La Paz University Hospital, Translational Research Unit in Paediatric Haemato-Oncology, Hematopoietic Stem Cell  transplantation and Cell Therapy.
  • P2-18. CXCL9 AS BIOMARKER FOR TREATMENT ADJUSTMENT IN THE INMUNOTHERAPY WITH EMAPALUMAB
    
    Aguilar Concepción, Daniela¹; Miguel Berenguel, Laura¹; Cuesta Martín De La Cámara, Ricardo¹; Robles Marhuenda, Ángel²; Bardón Cancho, Eduardo Jesús³; García-Morin, Marina³; Cámara Hijón, Carmen¹.
    
    ¹Department of Immunology, Hospital Universitario La Paz; ²Department of Internal Medicine, Hospital Universitario La Paz; ³Department of Pediatric Hemato-oncology, Hospital Universitario Gregorio Marañón; Faculty of Medicine, Universidad Complutense de Madrid; Instituto de Investigación Sanitaria Gregorio Marañón.
  • P2-19. Strengthened Influenza Immunization: Vaccination protects against Co-infection and Superinfection by Influenza Virus and Streptococcus pneumoniae
    
    Arranz Herrero, Javier¹; García-Bernalt Diego, Juan²; Laghlali, Gabriel²; Park, Seokchan²; Singh, Gagandeep²; Chang, Lauren²; Ochando, Jordi³; Nistal-Villan, Estanislao¹; Schotsaert, Michael².
    
    ¹Fundacion Universitaria CEU San Pablo; ²Icahn School of Medicine at Mount Sinai; ³Instituto de Salud Carlos III.